Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy
Oct 28, 2024•12 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, Dr. Valentin Fuster explores groundbreaking research on hypertrophic cardiomyopathy, focusing on the effects of the drug aficamten on cardiac structure and function. Highlighting significant findings from the Sequoia HCM trial, the discussion underscores the potential of aficamten to induce favorable cardiac remodeling and improve patient outcomes, signaling a transformative era in the management of this condition.
For the best experience, listen in Metacast app for iOS or Android